ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT)
CUSIP: H0036K147
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Shares, par value CHF 0.08 per share
- Shares outstanding
- 128,459,465
- Total 13F shares
- 68,158,412
- Share change
- -2,717,131
- Total reported value
- $272,625,712
- Put/Call ratio
- 172%
- Price per share
- $4.00
- Number of holders
- 105
- Value change
- -$9,526,921
- Number of buys
- 53
- Number of sells
- 26
Quarterly Holders Quick Answers
What is CUSIP H0036K147?
CUSIP H0036K147 identifies ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP H0036K147:
Top shareholders of ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC |
13F
|
Company |
12%
|
15,666,731
|
$41,986,839 | — | 30 Jun 2025 | |
| Prosight Management, LP |
13F
|
Company |
8.1%
|
10,467,771
|
$28,053,626 | — | 30 Jun 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
6%
|
7,763,658
|
$20,806,603 | — | 30 Jun 2025 | |
| Oaktree Capital Group Holdings GP, LLC |
13D/G
|
Oaktree Fund Administration, LLC |
4.1%
|
4,673,441
|
$18,693,764 | $0 | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
4.6%
|
5,907,351
|
$15,831,701 | — | 30 Jun 2025 | |
| HPWH TH AG |
13D/G
|
Dr. Hans-Peter Wild |
9.6%
|
9,788,944
|
$14,291,858 | $0 | 15 May 2025 | |
| Hans Peter Wild |
3/4/5
|
10%+ Owner |
7.6%
|
9,788,944
|
$14,291,858 | — | 15 May 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5%
from 13D/G
|
4,521,343
|
$12,117,199 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.4%
|
3,045,573
|
$8,162,136 | — | 30 Jun 2025 | |
| HEIGHTS CAPITAL MANAGEMENT, INC |
13F
|
Company |
2.2%
|
2,832,861
|
$7,592,067 | — | 30 Jun 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.8%
|
2,266,289
|
$6,073,655 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.7%
|
2,199,059
|
$5,893,478 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
1,542,602
|
$4,134,173 | — | 30 Jun 2025 | |
| PLATINUM INVESTMENT MANAGEMENT LTD |
13F
|
Company |
1.1%
|
1,387,265
|
$3,717,870 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.96%
|
1,234,473
|
$3,308,388 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.67%
|
858,796
|
$2,301,572 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.66%
|
842,900
|
$2,258,972 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.64%
|
827,575
|
$2,217,901 | — | 30 Jun 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.57%
|
733,568
|
$1,965,962 | — | 30 Jun 2025 | |
| Vantage Consulting Group Inc |
13F
|
Company |
0.53%
|
682,998
|
$1,830,435 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.47%
|
597,792
|
$1,602,083 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.44%
|
560,523
|
$1,502,201 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.33%
|
426,886
|
$1,144,054 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.3%
|
383,674
|
$1,028,246 | — | 30 Jun 2025 | |
| Peter Hug |
3/4/5
|
Director |
0.17%
|
220,500
|
$789,390 | — | 13 Jun 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.22%
|
283,286
|
$759,206 | — | 30 Jun 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.21%
|
271,359
|
$727,242 | — | 30 Jun 2025 | |
| Viviane Monges |
3/4/5
|
Director |
0.11%
|
144,043
|
$515,673 | — | 13 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.14%
|
182,012
|
$487,792 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.12%
|
158,135
|
$423,802 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.11%
|
145,407
|
$389,690 | — | 30 Jun 2025 | |
| Victor Sandor |
3/4/5
|
Director |
0.08%
|
108,286
|
$387,663 | — | 13 Jun 2025 | |
| Jean-Pierre Bizzari |
3/4/5
|
Director |
0.08%
|
106,902
|
$382,709 | — | 13 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.11%
|
140,580
|
$376,754 | — | 30 Jun 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.1%
|
132,218
|
$354,344 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
0.1%
|
131,865
|
$353,398 | — | 30 Jun 2025 | |
| Ron Squarer |
3/4/5
|
Director |
0.07%
|
93,627
|
$335,184 | — | 13 Jun 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.1%
|
122,081
|
$327,177 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.09%
|
118,915
|
$318,693 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.09%
|
115,232
|
$308,822 | — | 30 Jun 2025 | |
| Florida Trust Wealth Management Co |
13F
|
Company |
0.09%
|
113,000
|
$302,840 | — | 30 Jun 2025 | |
| Robert Azelby |
3/4/5
|
Director |
0.06%
|
80,405
|
$287,849 | — | 13 Jun 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.08%
|
102,608
|
$274,981 | — | 30 Jun 2025 | |
| Wilmington Savings Fund Society, FSB |
13F
|
Company |
0.08%
|
100,000
|
$268,000 | — | 30 Jun 2025 | |
| Thomas Pfisterer |
3/4/5
|
Other* |
0.14%
|
173,899
|
$253,892 | — | 15 May 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.05%
|
62,441
|
$167,342 | — | 30 Jun 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.05%
|
59,548
|
$160,000 | — | 30 Jun 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.04%
|
56,062
|
$150,246 | — | 30 Jun 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.04%
|
49,590
|
$132,901 | — | 30 Jun 2025 | |
| MetLife Investment Management, LLC |
13F
|
Company |
0.04%
|
45,027
|
$120,672 | — | 30 Jun 2025 |
Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q3 2025
As of 30 Sep 2025,
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) was held by
105 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
68,158,412 shares.
The largest 10 holders included
Redmile Group, LLC, Point72 Asset Management, L.P., Prosight Management, LP, ORBIMED ADVISORS LLC, BlackRock, Inc., MORGAN STANLEY, Nantahala Capital Management, LLC, GOLDMAN SACHS GROUP INC, TCG Crossover Management, LLC, and BANK OF AMERICA CORP /DE/.
This page lists
105
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
84
Q3 2025 holders
105
Holder diff
21
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.